$ABT

$ABT - Late-breaking one-year data show Abbott's next-generation Amulet 360™ device continues to demonstrate high rates of left atrial appendage closu…

$ABT Abbott's TECTONIC clinical trial demonstrates strong 30-day outcomes and high procedural success for its investigational SonicForce™ Coronary Int…

$ABT - Abbott initiates pivotal trial for Cephea™ device, an innovative treatment for mitral heart valve disease…

$ABT - Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment…

$ABT - Abbott presents new ESMO data showing 30-percent absolute improvement in sensitivity with the whole-genome sequencing Oncodetect® test in color…

$ABT ABBOTT Q3 EARNINGS - ADJ EPS: $1.42 (EST $1.42) - NET SALES: $13.01B (EST $13B) - COMPARABLE SALES: +7% - SEES Q4 ADJ EPS: $1.62 TO $1.67 (EST $1…

$ABT - Abbott Reports Third-Quarter 2026 Results and Reaffirms Full-Year EPS Guidance…

$ABT ABBOTT ANNOUNCES ITS INTENTION TO SEPARATE ITS GLOBAL NUTRITION BUSINESS INTO AN INDEPENDENT, PUBLICLY TRADED COMPANY -SEPARATION EXPECTED TO BE…

$ABT - Abbott introduces Ensure® Max Protein 3-in-1 Muscle Support, bringing the benefits of a supplement stack into one scoop…

$ABT - Abbott hosts conference call for third-quarter earnings…

$ABT - Abbott And Berry Street Partner To Expand Personalized Nutrition Support For Consumers Seeking Better Metabolic Health…

$ABT - Abbott declares 411th consecutive quarterly dividend…

$ABT - Abbott reaches agreement with Department of Justice to resolve claims relating to 2022 infant formula recall…

$ABT - Abbott receives FDA approval for its TactiFlex™ Duo Ablation Catheter to treat people with abnormal heart rhythms…

$ABT - Abbott launches the first and only ready-to-feed liquid infant formula made with whole milk in the U.S. at similar price to its existing Simila…